"Nvidia's $50 Million Investment Boosts AI Drug Discovery with Recursion"

Nvidia has invested $50 million in biotech firm Recursion to accelerate the training of its artificial intelligence (AI) models for drug discovery. Recursion will use Nvidia's cloud platform to train AI models using its own extensive biological and chemical datasets. The AI models could then be licensed to other biotech firms through Nvidia's generative AI cloud service for drug discovery. Recursion, which has partnerships with Bayer and Roche, plans to utilize Nvidia's software to support its own pipeline and collaborations. The investment from Nvidia will help further advance Recursion's AI-driven drug discovery efforts.